A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
publication date
has subject area
published in
Research
keywords
32 Biomedical and Clinical Sciences
3211 Oncology and Carcinogenesis
5.1 Pharmaceuticals
6.1 Pharmaceuticals
6.2 Cellular and gene therapies
Biotechnology
Cancer
Clinical Research
Clinical Trials and Supportive Activities
Health Disparities
Hematology
Immunotherapy
Minority Health
Orphan Drug
Patient Safety
Rare Diseases
Identity
Digital Object Identifier (DOI)
Additional Document Info
start page
end page
volume
issue
